Outcome for adolescent and young adult patients with osteosarcoma: a report from the Children's Oncology Group. - Wikidata - awgldk - TriplyDB

Outcome for adolescent and young adult patients with osteosarcoma: a report from the Children's Oncology Group.

Outcome for adolescent and young adult patients with osteosarcoma: a report from the Children's Oncology Group.

http://www.wikidata.org/entity/Q33559539

about

UK guidelines for the management of bone sarcomas A summary of the osteosarcoma banking efforts: a report from the Children's Oncology Group and the QuadW Foundation Osteosarcoma in pediatric patients and young adults: a single institution retrospective review of presentation, therapy, and outcome Epidemiology and therapies for metastatic sarcoma In silico functional analyses and discovery of survival-associated microRNA signatures in pediatric osteosarcoma.Apurinic/apyrimidinic endonuclease 1 induced upregulation of fibroblast growth factor 2 and its receptor 3 induces angiogenesis in human osteosarcoma cells.Outcomes of Adolescent and Adult Patients with Lung Metastatic Osteosarcoma and Comparison of Synchronous and Metachronous Lung Metastatic Groups Children's Oncology Group's 2013 blueprint for research: adolescent and young adult oncology.Inhibition of protein phosphatase 2A with the small molecule LB100 overcomes cell cycle arrest in osteosarcoma after cisplatin treatment.Aberrant Retinoblastoma (RB)-E2F Transcriptional Regulation Defines Molecular Phenotypes of Osteosarcoma.Identification of Synergistic, Clinically Achievable, Combination Therapies for Osteosarcoma Improvement in High-Grade Osteosarcoma Survival: Results from 202 Patients Treated at a Single Institution in Taiwan Activation of PTHrP-cAMP-CREB1 signaling following p53 loss is essential for osteosarcoma initiation and maintenance.AYA in the USA. International Perspectives on AYAO, Part 5.Analysis of serum insulin growth factor-1 concentrations in localized osteosarcoma: a children's oncology group study Cytotoxic effects of 15d-PGJ2 against osteosarcoma through ROS-mediated AKT and cell cycle inhibition.Giant cell-rich osteosarcoma in long bones: clinical, radiological and pathological features.Clinical trial enrollment of adolescents and young adults with sarcoma.HSP70 desensitizes osteosarcoma cells to baicalein and protects cells from undergoing apoptosis.Disparities in Adolescents and Young Adults With Cancer Proteomic identification of 14-3-3ϵ as a linker protein between pERK1/2 inhibition and BIM upregulation in human osteosarcoma cells.Biologic activity of the novel small molecule STAT3 inhibitor LLL12 against canine osteosarcoma cell lines.Venous tumor thrombus from a pelvic osteosarcoma.Prognostic value of FDG-PET indices for the assessment of histological response to neoadjuvant chemotherapy and outcome in pediatric patients with Ewing sarcoma and osteosarcoma.pFAK-Y397 overexpression as both a prognostic and a predictive biomarker for patients with metastatic osteosarcoma.Systematic Screening Identifies Dual PI3K and mTOR Inhibition as a Conserved Therapeutic Vulnerability in Osteosarcoma.Emodin inhibits HMGB1-induced tumor angiogenesis in human osteosarcoma by regulating SIRT1.Influence of ezrin-shRNA in combination with HSP70 on the apoptosis and proliferation of osteosarcoma cells.Diagnostic assessment of osteosarcoma chemoresistance based on Virtual Clinical Trials.Experience of pediatric osteosarcoma of the extremity at a single institution in Taiwan: prognostic factors and impact on survival.Osteosarcoma in patients younger than 12 years old without metastases have similar prognosis as adolescent and young adults.Response Evaluation Criteria in Solid Tumors (RECIST) following neoadjuvant chemotherapy in osteosarcoma.Primary metastatic osteosarcoma: results of a prospective study in children given chemotherapy and interleukin-2.FDG PET/CT appearance of local osteosarcoma recurrences in pediatric patients.The extremity localized classic osteosarcomas have better survival than the axial non-classics.Prognostic Value of Vascular Invasion in Pediatric Osteosarcomas.miR-34 inhibits growth and promotes apoptosis of osteosarcoma in nude mice through targetly regulating TGIF2 expression.18F-FDG Uptake During Early Adjuvant Chemotherapy Predicts Histologic Response in Pediatric and Young Adult Patients with Osteosarcoma.Adenovirus-mediated small interfering RNA targeting ezrin induces apoptosis and inhibits metastasis of human osteosarcoma MG-63 cells Radiological characteristics and predisposing factors of venous tumor thrombus in pelvic osteosarcoma: A mono-institutional retrospective study of 115 cases

P2860

Q26752425-712EDEC6-26CE-42AF-82A8-8337EF5CB1E0 Q28386370-7FA428C4-FA8F-4713-873D-B3AB61318770 Q33614621-47CEF4A4-6CD2-41CA-9589-8F8ED02396DC Q34652142-F8BFC32E-15A3-4CB7-AB40-B1900758609D Q34781386-4BAE7D5C-4537-4A85-87EB-34025754AD3A Q35051513-8ACA0DFD-A34A-4BA2-AA99-262A73EFE16D Q36014443-E441FAF9-1F4E-4514-89E8-EC4FFE65E6A9 Q36157250-3E80A841-4B93-45BA-91C8-B70E1C4F2BEF Q36180744-83238070-816B-4CB2-A3A2-07FFBBD191FA Q36301216-D0A56353-5764-4066-872E-BC9E14799821 Q36316518-570B2DBA-4C30-4ADD-B454-5FFC95F2313D Q36822586-30FB9797-3887-418D-8AC5-D9DBEC9D2A23 Q36862527-49948C43-45DB-4958-B23A-B70D8DD7F145 Q37406641-7F44A1E1-E162-4C44-AF5D-588C83B891A0 Q37624249-B1937825-4391-464B-A885-06720F5EF06E Q37718423-2896A348-6B86-4E38-BAC3-62E7EB64E63A Q38110244-D6BFC1BA-467A-458B-973D-A419211E4DA7 Q38685233-859C6E93-E35A-43D8-AA26-EEE967DD4CB4 Q38993208-6ABF0984-A34F-4F55-9DAF-A89D1EF8DB6A Q39008035-F0EA122D-D37B-417A-9799-BFEE8E4352E1 Q39023037-7423A75E-4C11-474D-9EE9-D1F99F07E481 Q39225305-0F68BCCB-AB35-40BD-83FA-2C77FA5E61D5 Q39664957-C5DC686B-1EAB-4FF0-8601-AC9E78734B10 Q41523153-1FFAB64B-1136-42CD-8BD3-71A68A6D1308 Q41533133-C544EF26-2ABB-4683-9F45-7701623E416E Q41764229-3FD88488-BE3C-484B-8278-2BD007310DF6 Q41995659-602026B9-CFF0-4B88-98FE-31FFBE2A1090 Q42370628-6D82BB07-79FB-44F4-B2CE-588A3FA93F3D Q42843612-D54604C2-7653-44B8-AF51-5A5A213BD028 Q43588156-B83323BF-B3FA-4FEB-9338-BD7D2431EF9A Q43645139-1D9436FA-5F8F-4449-851E-925940BE441A Q48101407-23759377-C09F-4F08-B3F9-14858C54AB86 Q48378796-9542975C-73A9-4C1C-87AD-E4ECE0866F1F Q50193590-D4CB65AF-0BE3-423C-8EC2-0D6FC77A496D Q50315172-F36B316D-C1CF-41C4-AE77-E943EEB45835 Q50849056-6AD12B76-4FD6-44E2-A232-8F50537F7F06 Q55121974-D4D27D55-39A2-419C-8269-A0AC3AAE2D4D Q55362893-855EFEEC-9E36-45FE-A16D-BDCBDB7CA410 Q58693569-82557CDE-5F03-4E54-BE5E-6993C067D6B0 Q58709616-A11B9ED7-14A0-4D1C-A9BA-0426D7052FBE

P2860

Outcome for adolescent and young adult patients with osteosarcoma: a report from the Children's Oncology Group.

http://www.wikidata.org/entity/Q33559539

description

2012 nî lūn-bûn

@nan

2012 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Outcome for adolescent and you ...... the Children's Oncology Group.

@ast

Outcome for adolescent and you ...... the Children's Oncology Group.

@en

Outcome for adolescent and you ...... the Children's Oncology Group.

@nl

type

label

Outcome for adolescent and you ...... the Children's Oncology Group.

@ast

Outcome for adolescent and you ...... the Children's Oncology Group.

@en

Outcome for adolescent and you ...... the Children's Oncology Group.

@nl

prefLabel

Outcome for adolescent and you ...... the Children's Oncology Group.

@ast

Outcome for adolescent and you ...... the Children's Oncology Group.

@en

Outcome for adolescent and you ...... the Children's Oncology Group.

@nl

P1433

Q33559539-8CFCB758-B37A-4300-8BFC-F80D806D7564

P1476

Q33559539-D84F8A4A-8CF5-4A7C-8936-DB0BFDB9DA55

P2093

Q33559539-16A4E854-F5D3-42DF-8376-F03D047ACA12

Q33559539-3E00C841-0B72-4690-9363-D30147804D66

Q33559539-699AAD45-7A34-49CC-A792-A3CDE46E0E5D

Q33559539-9A6DCC88-AD67-4EE7-9648-35B4628BA4A1

Q33559539-CBD8BCC4-23E8-429C-AAE7-BD0BE0EED599

Q33559539-D107F841-516D-42EA-A4AE-C2DD3E633312

Q33559539-E01363CA-59E2-499A-BFA5-BCF5DFD8E858

P2860

Q33559539-0098ADAD-929B-4673-91AD-FE5986817F40

Q33559539-08F29FA8-44E2-4231-91AD-097A38C082C9

Q33559539-0D6DF32C-C154-49F1-A56D-A9F224E4BF3B

Q33559539-2BDEC0C1-F946-4B60-974C-13479E055945

Q33559539-33801A30-6BCA-40A4-BE32-A7A3A992F93D

Q33559539-7E46D011-043A-4C60-B27A-2E62301186F4

Q33559539-88333B38-4228-489F-8D33-BE0BC7D6C12B

Q33559539-965B00DE-0855-4499-AB22-F22226894D5E

Q33559539-A0F9D597-330A-4CEE-B51A-921648E060E4

Q33559539-AB7047B8-0694-4183-B88F-5D08121690A5

P304

Q33559539-213A8B0D-6323-40FE-BBA3-144C5EAA1883

P31

Q33559539-83D3A952-8845-42EE-8BA4-EBD5DE5968F8

P356

Q33559539-ED67A30F-7166-4F27-9DF3-160F93A38700

P407

Q33559539-3A961975-36FD-48FD-B8A9-11FE44D372B9

P433

Q33559539-B063109D-A77D-4F20-97F7-619CA597B1D0

P478

Q33559539-AE74DAEF-03F1-499F-9DB6-13E16315C258

P50

Q33559539-116CDE53-8BB4-4690-93BB-54469BCC7025

Q33559539-B051657E-5FD7-4C84-A4AB-745D347F4730

Q33559539-EFAC2B13-CE58-4624-88B1-88A4F853B8D7

P577

Q33559539-88417A95-145C-4DBF-BB15-2B403E050BC3

P5875

Q33559539-8231E636-0FAA-433B-81AB-D8AFCC0E41F9

P698

Q33559539-A3BE7C28-EDB8-4C99-95E4-BFB96226FB36

P921

Q33559539-52EA5306-5665-4672-8449-F4A8363DCE27

Q33559539-6086D392-1972-4CE7-878A-0273546D431C

P932

Q33559539-BA8B4DF5-375C-4174-960C-400CCB576681

P356

P1433

P1476

Outcome for adolescent and you ...... the Children's Oncology Group.

@en

P2093

Cindy L Schwartz

http://www.w3.org/2001/XMLSchema#string

David H Ebb

http://www.w3.org/2001/XMLSchema#string

Donald A Barkauskas

http://www.w3.org/2001/XMLSchema#string

Holcombe E Grier

http://www.w3.org/2001/XMLSchema#string

Katherine A Janeway

http://www.w3.org/2001/XMLSchema#string

Mark D Krailo

http://www.w3.org/2001/XMLSchema#string

Neyssa Marina

http://www.w3.org/2001/XMLSchema#string

P2860

Estimation of failure probabilities in the presence of competing risks: new representations of old estimators.

Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate.

Comparing children and adults with synovial sarcoma in the Surveillance, Epidemiology, and End Results program, 1983 to 2005: an analysis of 1268 patients.

Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.

The distinctive biology of cancer in adolescents and young adults.

Tumor size and prognosis in aggressively treated osteosarcoma.

Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity: an analysis of 300 patients treated at the Rizzoli Institute.

Comparing adult and pediatric rhabdomyosarcoma in the surveillance, epidemiology and end results program, 1973 to 2005: an analysis of 2,600 patients.

Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone.

Age as a prognostic factor for patients with osteosarcoma: an analysis of 438 patients.

P304

4597-4605

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.27414

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

118

http://www.w3.org/2001/XMLSchema#string

P50

Richard G Gorlick

P577

2012-01-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221754483

http://www.w3.org/2001/XMLSchema#string

P698

22252521

http://www.w3.org/2001/XMLSchema#string

P921

P932

4008337

http://www.w3.org/2001/XMLSchema#string